Universität zu Köln

Eichenauer, Dennis A. ORCID: 0000-0002-1927-3514, Basaran, Aylin, Bühnen, Ina, Fuchs, Michael ORCID: 0000-0003-3289-3272, von Tresckow, Bastian ORCID: 0000-0003-1410-4487, Rosenwald, Andreas, Hansmann, Martin-Leo, Bernd, Heinz-Wolfram, Borchmann, Peter ORCID: 0000-0003-3782-2158, Klapper, Wolfram ORCID: 0000-0001-7208-4117 and Hartmann, Sylvia ORCID: 0000-0003-3424-1091 (2025). Refining histopathological growth pattern-based risk group discrimination in nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Leukemia, 39 (7). pp. 1735-1743. Springer Nature. ISSN 0887-6924

PDF s41375-025-02641-3.pdf Bereitstellung unter der CC-Lizenz: Creative Commons Attribution. Download (4MB)

Abstract

Histopathological growth patterns (GP) in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) have previously been divided into GP AB (typical) vs CDEF (variant). However, it is unclear whether this division is optimal. We thus investigated alternative GP grouping approaches (GP ABC vs DEF; GP ABCF vs DE). Overall, 583 NLPHL patients who had first-line treatment within GHSG trials were included in the analysis. Median age was 39 years; 74% of patients were male; 76% presented with early-stage and 24% with advanced-stage disease. The 5-year and 10-year progression-free survival (PFS) estimates for all patients were 85.9% and 76.6%; overall survival (OS) estimates were 95.8% and 94.5%. Significant PFS and OS differences were detected for the comparison GP ABCF vs DE with worse outcomes for the GP DE group (HR: 1.7; 95%-CI: 1.1–2.7; HR: 2.5; 95%-CI: 1.1–5.7). No PFS and OS differences were observed for the comparisons GP AB vs CDEF and GP ABC vs DEF. Median time to death was shorter and death more often due to NLPHL in the GP DE (13 months; 66.7%) than in the GP ABCF (31 months; 5.6%) group. Hence, the division of GP into GP ABCF vs DE allows an optimized GP-based risk group discrimination in NLPHL.

Item Type:	Article
Creators:	Creators Email ORCID ORCID Put Code Eichenauer, Dennis A. UNSPECIFIED https://orcid.org/0000-0002-1927-3514 UNSPECIFIED Basaran, Aylin UNSPECIFIED UNSPECIFIED UNSPECIFIED Bühnen, Ina UNSPECIFIED UNSPECIFIED UNSPECIFIED Fuchs, Michael UNSPECIFIED https://orcid.org/0000-0003-3289-3272 UNSPECIFIED von Tresckow, Bastian UNSPECIFIED https://orcid.org/0000-0003-1410-4487 UNSPECIFIED Rosenwald, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Hansmann, Martin-Leo UNSPECIFIED UNSPECIFIED UNSPECIFIED Bernd, Heinz-Wolfram UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, Peter UNSPECIFIED https://orcid.org/0000-0003-3782-2158 UNSPECIFIED Klapper, Wolfram UNSPECIFIED https://orcid.org/0000-0001-7208-4117 UNSPECIFIED Hartmann, Sylvia UNSPECIFIED https://orcid.org/0000-0003-3424-1091 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-805890
Identification Number:	10.1038/s41375-025-02641-3
Journal or Publication Title:	Leukemia
Volume:	39
Number:	7
Page Range:	pp. 1735-1743
Number of Pages:	9
Date:	13 July 2025
Publisher:	Springer Nature
ISSN:	0887-6924
Language:	English
Faculty:	Faculty of Medicine
Divisions:	Faculty of Medicine > Innere Medizin > Klinik I für Innere Medizin - Hämatologie und Onkologie Faculty of Medicine > Weitere > Centrum für integrierte Onkologie (CIO)
Subjects:	Medical sciences Medicine
['eprint_fieldname_oa_funders' not defined]:	Publikationsfonds UzK
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/80589